Understanding this sensorimotor disorder, its pathophysiology, and evidence-based treatment approaches
RLS is a clinical diagnosis based on patient-reported symptoms. The International Restless Legs Syndrome Study Group established five essential diagnostic criteria, all of which must be met.
1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.
3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
4. The urge to move or unpleasant sensations are worse in the evening or at night than during the day, or only occur in the evening or night (circadian pattern).
5. The symptoms are not solely accounted for by another medical or behavioral condition (leg cramps, positional discomfort, myalgia, venous stasis, leg edema, arthritis, habitual foot tapping).
Patients describe RLS sensations in various ways:
Importantly, patients describe an irresistible urge to move—not just discomfort. The sensations typically occur in the calves but can affect thighs, feet, and even arms. Symptoms are usually bilateral but can be asymmetric.
RLS symptoms peak in the evening and night, making sleep initiation extremely difficult. Patients may delay bedtime, spend hours trying to fall asleep, or repeatedly get out of bed to walk and relieve symptoms. This results in severe sleep onset insomnia, reduced total sleep time, daytime fatigue and sleepiness, impaired quality of life, and depression and anxiety.
Brain iron deficiency—particularly in the substantia nigra—is central to RLS pathophysiology. Iron is a critical cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. MRI and autopsy studies show reduced iron in specific brain regions in RLS patients despite normal or even elevated peripheral iron stores. This suggests a problem with iron transport across the blood-brain barrier or cellular iron regulation.
Importantly, RLS symptoms can occur even with normal serum ferritin, but are consistently worse when ferritin is low. Serum ferritin <75 mcg/L is associated with RLS severity, and iron supplementation can significantly improve symptoms.
RLS involves altered dopaminergic neurotransmission in the diencephalospinal pathway (A11 dopaminergic cell group). This pathway projects to the spinal cord and modulates sensory processing and motor control. The circadian worsening of RLS symptoms parallels the normal circadian decrease in dopamine and iron in the brain.
Paradoxically, while dopamine agonists are effective RLS treatments, there is no clear dopamine deficiency in RLS (unlike Parkinson's disease). The dysfunction appears to involve dopamine receptor sensitivity and altered post-synaptic signaling.
RLS has strong genetic components with 40-60% heritability. Genome-wide association studies have identified multiple risk variants in genes involved in neuronal development, iron regulation (particularly MEIS1, BTBD9), and glutamatergic signaling. Early-onset RLS (before age 45) typically has stronger familial aggregation.
RLS can be primary (idiopathic) or secondary to underlying conditions. All RLS patients should be evaluated for reversible causes.
The most important potentially reversible cause. Check serum ferritin in all RLS patients. Target ferritin >75 mcg/L, ideally >100 mcg/L. Iron supplementation can dramatically improve or resolve symptoms when deficiency is corrected.
RLS affects 20-30% of pregnant women, typically worsening in the third trimester. It's likely related to iron deficiency, folate deficiency, and hormonal changes. Symptoms usually resolve after delivery. Treatment focuses on iron/folate supplementation and non-pharmacological measures.
RLS affects 20-40% of dialysis patients and correlates with dialysis duration and severity of uremia. Pathophysiology involves uremic toxins, anemia, iron deficiency, and peripheral neuropathy. Treatment includes optimizing dialysis adequacy, correcting anemia and iron deficiency, and potentially kidney transplantation.
Many commonly prescribed medications exacerbate RLS:
Review all medications in RLS patients and discontinue exacerbating agents when possible.
Medication is indicated for RLS that significantly impacts sleep or quality of life despite addressing secondary causes.
Gabapentin or pregabalin are now considered first-line therapy for most RLS patients due to efficacy and avoidance of augmentation.
Side effects: Dizziness, sedation, weight gain, peripheral edema. Dose-adjust for renal impairment.
Augmentation is a worsening of RLS symptoms due to dopaminergic treatment, occurring in up to 70% of patients on long-term dopamine agonists. Characteristics:
Management requires switching to gabapentinoids or low-dose opioids. Prevention: use lowest effective dopamine agonist dose, maintain high iron stores, consider gabapentinoids first-line.
Learn more about sleep evaluation and testing
A sleep study can help evaluate periodic limb movements and other sleep-related findings in RLS. Learn what to expect during the process.
Read article → Sleep HealthMake sense of your sleep study report, including periodic limb movement data that's often relevant to RLS evaluation.
Read article →